Loading...
•
Mar 31, 2021
Regeneron Q1 2021 Earnings Report
Reported strong first-quarter results, marked by revenue growth and key pipeline advancements.
Key Takeaways
Regeneron reported a strong first quarter in 2021, with total revenues increasing by 38% to $2.53 billion. GAAP diluted EPS was $10.09, and non-GAAP diluted EPS was $9.89. The company saw significant growth in EYLEA U.S. net sales and Dupixent global net sales. Additionally, three FDA approvals were received for Libtayo and Evkeeza, and positive data was reported from Phase 3 trials with REGEN-COV.
Total revenues increased by 38% to $2.53 billion compared to the first quarter of 2020.
GAAP diluted EPS was $10.09, and non-GAAP diluted EPS was $9.89.
EYLEA U.S. net sales increased by 15% to $1.35 billion compared to the first quarter of 2020.
Dupixent global net sales increased by 48% to $1.26 billion compared to the first quarter of 2020.
Revenue by Segment
Forward Guidance
Regeneron provided full year 2021 financial guidance, including GAAP and Non-GAAP estimates for R&D, SG&A, gross margin, COCM, capital expenditures and effective tax rate.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...